Perioperative management of anticoagulation - Review of latest evidence

Arun Kannan, Chithra Poongkunran, Sundeep Shenoy, Aiden Abidov

Research output: Contribution to journalArticle

5 Scopus citations

Abstract

Periprocedural anticoagulation bridging is recommended to reduce the risk of thromboembolic events in patients at a higher risk of developing thromboembolism during the perioperative period. The optimal periprocedural anticoagulation strategy has not been established. Unfractionated heparin and low molecular heparin are used in preventing thromboembolism in the special population. Novel oral anticoagulants that directly inhibit thrombin (dabigatran) or factor Xa (rivaroxaban, apixaban) are shown as effective anticoagulants in preventing thromboembolism (venous thromboembolism) in various medical conditions. They have the advantage of having a faster onset, shorter half-lives, easier monitoring, and predicable doses. But there are disadvantages to newer anticoagulants such as the unavailability of definitive reversal agents and lack of data in patients with renal insufficiency. We review the latest evidence on the effects of newer oral anticoagulants in preventing thromboembolism and its bleeding risks.

Original languageEnglish (US)
Pages (from-to)e474-e484
JournalAmerican Journal of Therapeutics
Volume23
Issue number2
DOIs
StatePublished - Mar 1 2016

Keywords

  • anticoagulants
  • bleeding
  • periprocedural anticoagulation
  • thrombosis

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Perioperative management of anticoagulation - Review of latest evidence'. Together they form a unique fingerprint.

  • Cite this